OR WAIT null SECS
The company will aim to increase its employee headcount to meet the demand for one-stop-shop drug products manufacturing services.
Legacy Pharmaceuticals, a Switzerland-based contract manufacturer of sterile/aseptic pharmaceutical products in ampoules, vials, and semi-solids, announced it will aim to increase its employee headcount to 250 by the end of the year to meet the demand for one-stop-shop drug products manufacturing services.
“Being based in [Basel] we are fortunate to be able draw from a pool of highly educated and motivated staff-the region has [more than] 900 pharma and medtech companies employing [more than] 50,000 people,” said Mike Danzi, Legacy CEO, in an Oct. 29, 2019 press release. “This combination of motivation, skill, and experience is key to successful project transfer success and will ensure we can support both present and future customers in their drive to succeed in the increasingly competitive biologics market.”
According to the release, the company has been actively recruiting throughout the year which allowed for third shifts in semi-solids and steriles, the restructuring of the engineering department, additional quality assurance, validation, and qualification resources, and the expansion of the information technology organization.
“New employees tell us they value our breadth of products and the opportunities they have for further professional development,” Danzi said in the press release. “We actively encourage ownership of projects and creativity, while trying to foster a friendly supportive family environment. Because in the final analysis, spending money on new equipment and capacity means nothing if you do not have the right people to run it.”
Legacy Pharmaceuticals will be attending CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany. The company will be located at booth 121G72.
Source: Legacy Pharmaceuticals